NCT04044339View on ClinicalTrials.gov

Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

November 27, 2019

Study Completion Date

November 27, 2019

Conditions
Healthy
Interventions
DRUG

TD-5202

Study Drug to be administered orally

DRUG

Placebo

Placebo to be administered orally

Trial Locations (1)

68502

Theravance Biopharma Investigational Site, Lincoln

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY